Top-notch investors to help break the disability barrier
Wandercraft’s team announced on September 28th the closing of a Series B round of €15 million with five top-tier investors : XAnge, IDinvest, Cemag Invest and Bpifrance, followed by the company’s historical shareholder LBO France – Innovation Capital.
Wandercraft is the first company in the world to master the technologies required to design and control autonomous exos capable of human-like walk. The amount of equity raised is high for a medical robotics start-up.
This new equity will be used to obtain the first healthcare approvals, enter the global market of Rehabilitation Centers and develop the exo’s personal version.
World premieres in clinical trials
The exo’s first clinical trials have been conducted near Paris, and in the PM&R Rehab Center of Pionsat, in the center of France. For the first time, persons with complete SCI stood up and walked in an autonomous exo capable of providing a realistic gait.
To let wheelchair users walk again, Wandercraft develops the first exo that provides a realistic gait. Its technology is at the forefront of dynamic robotics and bio-mechanics. Disruptive algorithms, developed with the most advanced dynamic robotics academic labs. Controlling a robot with the 12 degrees of freedom required to mimic the human body.
Photo: Clinical trials of the autonomous exo (credit: Wandercraft)
Photo: Françoise walks with the autonomous exo (credit: Wandercraft)
Wandercraft has gathered, in Paris, France, one of the best walk robotics team. 35 mathematicians, roboticists and bio-mechanics experts supported by specialists in healthcare regulation and quality. All with one project: put the most advanced robotics at the service of mobility impaired persons.